U.S. Scrutiny of Chinese Company Could Disrupt U.S. Supply Chain for Key Drugs
The New York TimesLawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for canc…